VX-770 IN SUBJECTS 6 TO 11 YEARS WITH CYSTIC FIBROSIS AND THE G551D-CFTR MUTATION

被引：0
|
作者：
Aherns, R. [1 ]
Rodriguez, S. [2 ]
Yen, K. [2 ]
Davies, J. C. [3 ]
机构：
[1] Univ Iowa, Iowa City, IA USA
[2] Vertex Pharmaceut Inc, Cambridge, MA USA
[3] Royal Brompton Hosp, London SW3 6LY, England
来源：
PEDIATRIC PULMONOLOGY | 2011年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [41] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
    Donaldson, Scott H.
    Pilewski, Joseph M.
    Griese, Matthias
    Cooke, Jon
    Viswanathan, Lakshmi
    Tullis, Elizabeth
    Davies, Jane C.
    Lekstrom-Himes, Julie A.
    Wang, Linda T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 214 - 224
  • [42] EFFECT OF IVACAFTOR ON CIRCULATING INFLAMMATORY INDICES IN CF PATIENTS WITH THE G551D-CFTR MUTATION
    Seliger, V., I
    Accurso, F. J.
    Konstan, M. W.
    Dong, Q.
    Lubarsky, B.
    Mueller, P.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 298 - 299
  • [43] Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial
    Davies, Jane
    Sheridan, Helen
    Bell, Nicholas
    Cunningham, Steve
    Davis, Stephanie D.
    Elborn, J. Stuart
    Milla, Carlos E.
    Starner, Timothy D.
    Weiner, Daniel J.
    Lee, Po-Shun
    Ratjen, Felix
    LANCET RESPIRATORY MEDICINE, 2013, 1 (08): : 630 - 638
  • [44] A POINT MUTATION IN NBD1 CONFERS ATP-DEPENDENCE FOR G551D-CFTR
    Tsai, M.
    Li, M.
    Hwang, T.
    PEDIATRIC PULMONOLOGY, 2009, : 222 - 222
  • [45] HYPERPOLARIZED HELIUM-3 MAGNETIC RESONANCE IMAGING OF CFTR POTENTIATOR THERAPY IN SUBJECTS WITH CYSTIC FIBROSIS AND THE G551D MUTATION
    Altes, T.
    Johnson, M. A.
    Miller, G. W.
    Mugler, J. P.
    Flors, L.
    Mata, J.
    Salinas, C. L.
    Tustison, N.
    Lee, P.
    Song, T.
    Yen, K.
    Froh, D.
    Botfield, M. C.
    PEDIATRIC PULMONOLOGY, 2011, : 284 - 284
  • [46] PATIENT-REPORTED OUTCOMES IN PHASE 3 TRIALS OF IVACAFTOR IN SUBJECTS WITH CF WHO HAVE THE G551D-CFTR MUTATION
    Quittner, A.
    Ramsey, B.
    Rodriguez, S.
    Yen, K.
    Elborn, J. S.
    PEDIATRIC PULMONOLOGY, 2012, 47 : 297 - 297
  • [47] ADDITION OF VX-661, AN INVESTIGATIONAL CFTR CORRECTOR, TO IVACAFTOR, A CFTR POTENTIATOR, IN PATIENTS WITH CF AND HETEROZYGOUS FOR F508DEL/G551D-CFTR
    Donaldson, S. H.
    Pilewski, J. M.
    Cooke, J.
    Himes-Lekstrom, J.
    PEDIATRIC PULMONOLOGY, 2014, 49 : 308 - 309
  • [48] IVACAFTOR IN FRENCH PATIENTS WITH CYSTIC FIBROSIS AND A G551D MUTATION
    Hubert, D.
    David, V
    Rault, G.
    Dominique, S.
    Mely, L.
    Danner-Boucher, I
    Deneuville, E.
    Desrues, B.
    Grenet, D.
    Munck, A.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 286 - 286
  • [49] Clinical phenotype of cystic fibrosis patients with the G551D mutation
    Comer, D. M.
    Ennis, M.
    McDowell, C.
    Beattie, D.
    Rendall, J.
    Hall, V.
    Elborn, J. S.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2009, 102 (11) : 793 - 798
  • [50] Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
    Gelfond, Daniel
    Heltshe, Sonya
    Ma, Changxing
    Rowe, Steven M.
    Frederick, Carla
    Uluer, Ahmet
    Sicilian, Leonard
    Konstan, Michael
    Tullis, Elizabeth
    Roach, R. N. Christine
    Griffin, Katherine
    Joseloff, Elizabeth
    Borowitz, Drucy
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2017, 8
12345